Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Escin
RN: 6805-41-0
UNII: RUU8G67GQM
InChIKey: YFESOSRPNPYODN-RSMWSHJLSA-N

Note

  • Pentacyclic triterpene saponins, biosynthesized from protoaescigenin and barringtogenol, occurring in the seeds of AESCULUS. It inhibits edema formation and decreases vascular fragility.

Molecular Formula

  • C54-H84-O23

Molecular Weight

  • 2262.5208
 

Classification Codes

  • Antiviral (COVID-19)
  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Natural Product
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Escin

MeSH Heading

  • Escin

Synonyms

  • A-4700
  • Aescin
  • Aescin [German]
  • Aescusan
  • Amorphous aescin
  • EINECS 229-880-6
  • Escin
  • Escina
  • Escina [Italian]
  • Reparilu
  • Reparilu [Czech]
  • UNII-RUU8G67GQM

Systematic Name

  • Escin

Registry Numbers

CAS Registry Number

  • 6805-41-0

FDA UNII

  • RUU8G67GQM

Other Registry Numbers

  • 1394-90-7
  • 25255-37-2
  • 37-02-5
  • 47918-34-3
  • 55125-87-6

System Generated Number

  • 0006805410

Structure Descriptors

InChI

InChI=1S/2C55H86O24/c2*1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47/h2*10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70)/b23-10+;23-10-/t2*26?,27-,28-,29?,30?,31-,32?,33-,34-,35+,36+,37-,38-,39+,40+,41-,42+,43+,44+,47+,48+,49-,51+,52-,53-,54-,55+/m11/s1

InChIKey

YFESOSRPNPYODN-RSMWSHJLSA-N

Smiles

C\C=C(\C)/C(=O)O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CCC4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)C(=O)O)[C@](C)(CO)C5CC[C@@]34C)C2CC1(C)C.C\C=C(/C)\C(=O)O[C@H]9[C@H](OC(=O)C)[C@]%10(CO)[C@H](O)C[C@]%11(C)C(=CCC%12[C@@]%13(C)CCC(O[C@@H]%14O[C@@H]([C@@H](O[C@@H]%15O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%15O)[C@H](O)[C@H]%14O[C@@H]%16O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%16O)C(=O)O)[C@](C)(CO)C%13CC[C@@]%11%12C)C%10CC9(C)C

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 6700ug/kg (6.7mg/kg)   Drugs in Japan Vol. 6, Pg. APP-2, 1982.
mouse LD50 intravenous 2mg/kg (2mg/kg)   Bollettino Chimico Farmaceutico. Vol. 115, Pg. 272, 1976.
mouse LD50 oral 165mg/kg (165mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 8, Pg. 118, 1974.
mouse LD50 subcutaneous 38590ug/kg (38.59mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 8, Pg. 118, 1974.
rabbit LD50 intravenous 2500mg/kg (2500mg/kg) BLOOD: OTHER HEMOLYSIS WITH OR WITHOUT ANEMIA

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE"
Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 280, 1960.
rat LD50 intraperitoneal 10150ug/kg (10.15mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 8, Pg. 118, 1974.
rat LD50 intravenous 1600ug/kg (1.6mg/kg)   Bollettino Chimico Farmaceutico. Vol. 115, Pg. 272, 1976.
rat LD50 oral 833mg/kg (833mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 8, Pg. 118, 1974.
rat LD50 subcutaneous 150mg/kg (150mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 8, Pg. 118, 1974.